Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial
Brief Summary: Study Hypothesis: The addition of selenium supplementation to cotrimoxazole will improve CD4 counts, decrease opportunistic infections, decrease viral loads and delay the need for initiating antiretroviral therapy(ART) in Rwandan adult patients infected with HIV/ AIDS.


Options:
A: Inclusion Criteria:

* be an asymptomatic HIV infected adult
* at least 18 years of age
* have CD4+ cells between 375 and 750 cells/mm3
* have received no ART (excluding less than seven days and perinatal transmission prophylaxis)
* if a woman of child bearing potential, have a negative pregnancy test within two weeks prior to randomization and agree to practice barrier method of birth control during the study
* be willing and able to sign informed consent and to comply with the study protocol

Exclusion Criteria:

* have HIV-2 infection alone
* have known allergy or intolerance to any study medication ingredient
* be pregnant
* have active treatment for an acute opportunistic infection or malignancy
* have ALT greater than 3 x normal range
* have known cirrhosis of the liver
* have serum creatinine less than 133 umol/L
* abuse alcohol and recreational drugs
* be taking micronutrient (except vitamin D\*) or natural health product supplements within 30 days of randomization \*Maximum 2000 IU daily (Health Canada Guidelines).
B: Inclusion Criteria:

* Patients \> or = 21 years at enrollment
* Confirmed HIV positive with a CD4 range between 400 and 650 mm3
* HIV+ patients willing to participate in the study and who provide informed consent
* Pre-antiretroviral therapy (Pre-ART) at enrollment in study (not yet initiated ART)
* Willing to practice barrier method of birth control at all times

Exclusion Criteria:

* Patients intending to be transferred out of the clinic catchment area before study ends
* Patients scheduled to start ART
* Moribund patients
* Pregnant women
* Unable or not wanting to commit to barrier method of birth control
C: Inclusion Criteria:

* Sputum-confirmed pulmonary tuberculosis
* Resident of Zomba or Blantyre Districts, Malawi
* Willing to take tuberculosis chemotherapy as recommended by the National Tuberculosis Control Programme

Exclusion Criteria:

* Prior treatment for tuberculosis
D: Inclusion Criteria:

* Age ≥18 years
* Documented HIV infection
* Subjects must have taken HAART 6 months prior to study entry and must be on stable HAART (no dose change to antiretroviral medications) for at least 30 days immediately prior to study entry
* HDL \< 40 mg/dL • LDL \< 130 mg/dL
* All subjects with reproductive potential should utilize adequate contraception for the duration of this study and for at least 12 weeks following permanent discontinuation of study treatment. Acceptable methods include male condom, female condom, diaphragm, or intra-uterine device (IUD)

Exclusion Criteria:

* Known cardiac disease
* Arrhythmia
* History of angina
* Uncontrolled hypertension
* Pregnancy
* Breast-feeding
* Medication known to influence vasodilatation such as nitrates, metformin, pioglitazone, and rosiglitazone
* Heavy use of vitamin supplements
* Diagnosis of diabetes mellitus
* Treatment with lipid-lowering drugs within 6 weeks prior to study
* Hemoglobin \<9.0 mg/dL
* Absolute neutrophil count \<750 cells/mm3
* Platelet count \<75,000 platelets/ mm3
* Alanine aminotransferase (ALT or SGOT)/ aspartate aminotransferase (AST or SGPT) / alkaline phosphatase \> 2.5 x upper limit of normal (ULN)
* Creatinine \>1.5 x ULN
* Individuals with an infection or other medical illness requiring hospitalization within 14 days prior to study entry
* Individuals who have active alcohol or drug abuse which, in the investigator's opinion, is sufficient to prevent adequate compliance with study therapy and evaluations
* Prior history of hypersensitivity reaction to niacin or any other component of the study drug

Answer: B